List of Key Companies Profiled in the Europe Prothrombin Complex Concentrate Market Report: Quick Buy Europe Prothrombin Complex Concentrate Market Research Report: Such research studies proving the efficacy of PCC treatments, complemented by a rising number of older persons, will bolster the prospects of this market in Europe. Prothrombin complex concentrate has proven to be highly effective in treating patients with liver disease as they frequently develop coagulopathy.Ī study conducted in 2019 by researchers from the Royal Free Hospital, London and University College London found that PCC therapy was effective in improving coagulation test results in patients with liver disease, without any excess thrombotic events. Older persons are at a heightened risk of acute liver injury and also face increased susceptibility to the fibrotic response. Moreover, the European Commission (EC) predicts that the proportion of people above the age of 80 in the EU-27 will increase from 5.8% to 14.6% between 20. According to the latest data released by the UN’s Population Division, nearly 25% of Europe’s people are aged 60 years and above. Increasing Geriatric Populations across Europe to Create Market OpportunitiesĪn emerging factor driving the Europe prothrombin complex concentrate market growth is the rapidly aging populations across the continent. Further, the market in Scandinavia will be propelled by the strong presence and operations of CSL Behring in the region and the wide popularity of its prothrombin complex concentrate brand, Confidex. In the UK, on the other hand, the rising incidence of hemophilia B will be the principal growth driver for the country’s market. In 2019, the country’s market size stood at USD 46.0 million. Germany is anticipated to headline the Europe prothrombin complex concentrate market share during the forecast period owing to a large pool of patients suffering from congenital factor IX deficiency. Germany to Spearhead the Europe PCC Market the UK to Display Promising Growth Request a Sample Copy of the Research Report: This line of treatment offers a host of benefits, especially when compared to Fresh Frozen Plasma (FFP), a leading anticoagulation-reversal therapy.Īugust 2019: Octapharma AG announced the launch of its 4-factor prothrombin complex concentrate, Pronativ, indicated to arrest and reverse surgical blood loss. PCC (factor IX complex) is a medication comprising blood clotting factors II, IX, and X, indicated for treating bleeding in patients with hemophilia B. The substantial advantages offered by prothrombin complex concentrate (PCC) will be the primary driving force behind this market’s growth, forecasts Fortune Business Insights™ in its report, titled “Europe Prothrombin Complex Concentrate Market Size, Share & Covid-19 Impact Analysis, By Product (4-factor PCC and 3-factor PCC), By Application (Acquired Coagulation Deficiency and Congenital Coagulation Deficiency and By End User (Hospitals & Ambulatory Surgical Centers, Specialty Clinics, and Others), 2020-2027”. 09, 2021 (GLOBE NEWSWIRE) - The Europe prothrombin complex concentrate market size is projected to reach USD 398.9 million by 2027, exhibiting a CAGR of 10.9% during the forecast period. (Barcelona, Spain), Sanquin (Amsterdam, The Netherlands), Octapharma AG (Lachen, Switzerland), CSL Limited (Melbourne, Australia) and other key market players. Top Players Covered in the Europe Prothrombin Complex Concentrate Market Research Report are Takeda Pharmaceutical Company Limited (Tokyo, Japan), Kedrion S.p.A (Lucca, Italy), Grifols, S.A.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |